Six biopharmaceutical companies have completed a new round of financing! (May 7th)

Six biopharmaceutical companies have completed a new round of financing! (May 7th)

May 7, 2026 global, meritsip 0 Comments

Current biopharmaceutical financing updates: Nuanxin Jia has completed a strategic financing of 300 million yuan, leading the field of visual brain computer interfaces; Intelligent Diagnosis Technology’s 65 million yuan angel round landing accelerates the industrialization of medical AI big models; San Yan Biotechnology has completed its first round of financing exceeding 10 million yuan, and is laying out the domestic substitution of ECM medical beauty raw materials; Xinkanghe Biopharmaceutical has completed a financing of hundreds of millions of yuan, focusing on the fields of autoimmunity and tumor immunity; Weitao Biotechnology has completed over $50 million in Series A/A+financing, focusing on in vivo CAR-T therapy; Yilu Jiuge has completed its B+round of financing, accelerating the localization layout of medical devices going global. The medical hard technology and innovative drug track continue to attract gold.

1、 Nuanxin Jia has completed a strategic financing of 300 million yuan, leading the global field of visual brain computer interfaces

The global implantable visual brain computer interface track has ushered in a heavyweight capital layout. Hangzhou Nuanxinjia Electronic Technology Co., Ltd. recently completed a strategic financing of 300 million yuan. This round is jointly led by well-known industry investment institutions and Junlian Capital, with excess follow-up investment from Fengnian Capital and capital from Guangfa Xinde and Caitong. The core funds raised will be used for clinical promotion of visual reconstruction brain computer interface products, technological platform iteration, and capacity upgrading.

In recent years, brain computer interfaces have entered an explosive period driven by both policy and technology. By 2026, brain computer interfaces will be included in the national science and technology innovation strategy. Among them, implantable visual reconstruction has become a golden race track in the global field of neuromedical devices due to the huge clinical demand gap and extremely high technical barriers for severe blindness caused by genetic retinopathy and other diseases.

As a leader in the domestic visual brain computer interface field, Nuanxin Jia has advanced the dual technology route of retinal implantation and visual cortex implantation, and the core performance indicators of the two products it has released have entered the international top ranks. In terms of clinical progress, retinal pathway products have initiated human clinical trials, and visual cortex pathway products are expected to enter prospective clinical trials within the year, with commercialization progress ranking among the top in the world.

Unlike most start-up players in the industry who rely on external OEM supply chains, Nuanxin Jia has established a fully independent technology platform covering chip design, implantable device development, and compliant production. It has a complete 100000 level clean independent production line and was awarded the national level specialized and innovative “Little Giant Person” in 2024, with deep barriers between technology and supply chain. The investors believe that this round of financing will accelerate the commercialization of products, and Nuanxin is expected to promote the transformation of the global implantable brain computer interface industry, breaking the technological monopoly of overseas giants.

2、 65 million yuan angel round financing landed! Intelligent diagnosis technology accelerates the industrialization of medical AI big models

Recently, the domestic medical AI big model track has once again focused on financing. Hangzhou Zhijian Technology announced the completion of a 65 million yuan angel round of financing. This round of financing is jointly led by Hangzhou Qianyu Zhihui and Wuxi Yuanqi, with multiple industrial capital investors joining in. In addition to capital investment, the leading investor also introduces core R&D resources such as AI computing power into the project, laying a solid foundation for big model training and scenario implementation.

Since its establishment in 2023, Zhijian Technology has been continuously investing in the research and development of medical and health AI models, and continuously advancing capability iteration around its independently developed AI medical model WiseDiag. From early models to WiseDiag V2, the company has further strengthened the medical multimodal understanding capability of the model, enabling it to process various types of health data such as text, images, test reports, and physical sign photos. WiseDiag, the core technology base, aims to address the pain points of insufficient professionalism and poor compliance in the field of general large model medicine. Through precise adjustment of authoritative medical knowledge and optimization of clinical reasoning logic, it creates a highly specialized medical large model with underlying capabilities; Launch Haoban AI health management services for individual C-end users, covering universal needs such as daily health consultation and chronic disease follow-up management; The core benchmark product WiseClaw is positioned as the world’s first medical agent OS platform, which can help medical and health enterprises quickly build exclusive medical AI agents at low cost, significantly reducing the industry’s AI landing threshold.

At present, the company has reached cooperation agreements with several top clients in the medical and health industry. The funds raised in this round of financing will be used for model research and development iteration and product system construction, accelerating the transition of medical and health AI big models from technology display to real service scenarios, and solving the common industry problem of “difficult landing” of vertical big models.

3、 San Yan Biotechnology has completed its first round of financing exceeding 10 million yuan, accelerating the industrialization of medical beauty materials and ECM

Recently, Hangzhou Sanyan Biotechnology Co., Ltd. announced the completion of its first round of financing exceeding 10 million yuan, led by Jianchuang Medical Growth Fund. This round of financing is a landmark progress in the localization process of extracellular matrix (ECM) medical beauty raw materials in China.

Sanyan Biotechnology focuses on the innovation of high-end functional raw materials in the upstream of medical aesthetics. Its core subsidiary, Sansheng Meijian, takes the cross fusion of AI technology and synthetic biology as its core technology route, and has built an independent and controllable ECM functional raw material development platform, breaking through the industry pain points of insufficient purity, loss of activity, and high supply cost in the production of ECM raw materials using traditional extraction methods. It can achieve high-density heterologous expression of various core functional ECM raw materials such as recombinant humanized collagen and fibronectin, with both quality and cost advantages, filling the gap in large-scale production of domestic high-end ECM raw materials.

The funds raised in this round of financing will be used for the expansion of Sansheng Meijian’s production capacity, the upgrade of its AI synthetic biology technology platform, and the application for research and development of multiple compliant medical beauty pipeline raw materials, further deepening the company’s full chain layout in the ECM field.

The founder of Sanyan Biotechnology stated that this round of financing is an important milestone in the company’s development. The company will continue to deepen its ECM skincare and medical beauty track, rely on synthetic biology technology to solve the bottleneck problem of high-end raw materials, accelerate the process of domestic substitution of high-end medical beauty raw materials, and further increase research and development and production capacity investment in the future to promote the global market of domestic high-end medical beauty raw materials.

4、 Aomingxin Kanghe Biomedical has completed a new round of financing worth hundreds of millions of yuan, accelerating the clinical translation and marketization of innovative drugs

Recently, Xinkanghe Biopharmaceutical, an innovative biopharmaceutical company focusing on autoimmune diseases and immune tumors, announced the completion of a new round of financing worth hundreds of millions of yuan. This round of financing is led by Hillhouse Venture Capital and Beijing Sci Tech Innovation Yizhuang Direct Investment Fund, supported by the Beijing Medical and Health Industry Fund, with joint investment from Jiale Capital and Yuanxihai River.

This round of financing is an important capital boost completed after the company’s core pipeline achieved key clinical breakthroughs in registration. The company was founded by internationally renowned immunologist Academician Dong Chen, relying on innovative accumulation in the field of immune regulation, targeting the huge unmet clinical needs of autoimmune diseases in China, and building a differentiated innovative product pipeline. Multiple candidate drugs are in the first research and development echelon in China. The core asset XKH004 has successfully reached the end of its Phase III registered clinical research on psoriasis and ankylosing spondylitis, and is one of the few domestically developed high-quality pipelines of the same kind that has advanced to the later stage of registered clinical trials. It has the potential to be commercialized first; Another core project, XKH001 injection, is also steadily advancing clinical trials in multiple indications, demonstrating the advantages of differentiated treatment. As of now, the company has received support from over 15 well-known investment institutions, and its research and development strategy and pipeline value have been highly recognized by capital.

The funds raised in this round of financing will be used to advance clinical trials for core projects, iterate core technology platforms, expand pipelines, and build teams, accelerating the process of innovative drug launches. The investors expressed their strong recognition of the company’s innovative capabilities and commercialization potential at the source. This round of financing will help Xinkanghe accelerate the filling of the supply gap of innovative drugs in the domestic autoimmune field, benefiting more patients.

5、 Weitao Biotechnology has completed over $50 million in Series A and A+financing, focusing on in vivo CAR-T therapy

In the global field of cell therapy, in vivo CAR-T has become the core track for the next generation of innovative cell therapies due to its advantages of simplified preparation process, low treatment cost, and outstanding accessibility. Recently, the domestic track has received heavy capital support. Weitao Biotechnology, which focuses on innovative in vivo CAR-T development, recently announced the completion of consecutive Series A and A+rounds of financing, with a total financing amount of over 50 million US dollars: Series A led by Zhengxin Valley Capital, Series A+led by Decheng Capital, and multiple globally renowned medical and health investment institutions. After the completion of the A+round, Zhengxin Valley Capital and Decheng Capital have been nominated for board seats.

As a leading domestic in vivo CAR-T research and development enterprise, Weitao Biotech’s core pipeline GT801 targets unmet clinical needs for hematological malignancies and autoimmune diseases. Unlike traditional in vitro CAR-T that requires complex processes such as in vitro gene editing and cell amplification, GT801 can directly deliver functional CAR-T cells in vivo, significantly reducing treatment cycles and lowering treatment thresholds, solving the pain point of insufficient accessibility of mature in vitro CAR-T products. At present, GT801 has completed early clinical exploration, and preliminary human data will be announced at the American Society of Hematology (ASH) Annual Meeting in 2025. Current progress shows that it has demonstrated good safety and preliminary efficacy in subjects.

The funds raised this time will be used for the global clinical trial promotion and registration application of GT801, supporting the expansion of the R&D team and the iteration of the technology platform, and accelerating the company’s global layout. The capital side believes that in vivo CAR-T is the core iterative direction in the field of cell therapy, and Weitao’s pipeline progress and platform advantages have outstanding clinical and commercial potential.

6、 Medical device overseas platform Yilu Jiuge completes B+round financing, with Xinye Group leading the investment exclusively

Yilu Jiuge, a leading one-stop service platform for medical devices going global in China, recently completed a B+round of financing, which was exclusively invested by Xinye Group. This is also the third round of financing completed by the company in the past 18 months. The existing shareholders include Yongfeng County’s parent fund, Meihua Venture Capital, and Chengben Capital, among other industrial and financial investment institutions.

At present, China’s medical equipment going global has entered a period of structural transformation, and the industry has shifted from the early stage of “scale expansion” to the stage of brand and localized quality and efficiency improvement. The overseas model relying solely on cost-effectiveness advantages is no longer suitable for overseas regulatory requirements and market competition rules. The ability to provide localized services throughout the entire chain has become the core competitive barrier in the overseas market, and the demand for professional platform service providers in the market is rapidly increasing.

Founded in 2013, Yilu Jiuge is the earliest medical device cross-border S2B platform in China to layout a vertical track. Currently, its business covers 204 countries and regions worldwide, with an average annual compound growth rate of over 40% since its establishment, and its growth potential remains at the forefront of the track.

The funds raised in this round of financing will mainly be used to accelerate the global overseas warehouse network and target market compliance, marketing, and after-sales localization team building, further connecting the landing links of overseas services, and consolidating the leading position in the track. According to industry statistics, in the past 30 days, the domestic medical device market has completed 3 financing rounds exceeding 100 million US dollars and 5 B+round financing rounds. The attention of market capital continues to increase, and current competitors include Delta Pharmaceuticals. The exclusive investment of Xinye Group has verified the industrial value of the overseas service platform model. With the acceleration of the process of Chinese medical device brands going global, platform players with full chain localization capabilities will usher in long-term growth space.

-END-

About Us

MeritsIP: Your Global Intellectual Property Partner

At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.

M	T	W	T	F	S	S
				1	2	3
4	5	6	7	8	9	10
11	12	13	14	15	16	17
18	19	20	21	22	23	24
25	26	27	28	29	30	31

MeritsIP

MeritsIP